congenital heart disease
Conditions
Interventions
Case series:single intranasal dose of 2.0 mcg/kg Dexmedetomidine
Sponsors
Guangzhou Women and Chindren's Medical Center
Eligibility
Sex/Gender
All
Age
No minimum to 3 Years
Inclusion criteria
Inclusion criteria: 1. Infants and children scheduled to receive sedation/anesthesia for cardiac catheterization; 2. The subject must be a candidate to receive 2.5 mcg/kg or 3.0 mcg/kg of dexmedetomidine. A staff member of the Division of Cardiac Anesthesiology will make this decision; 3. The subjects must be 3 months to 36 months (inclusive of the 36th month); The subjects legally authorized representative has given written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: PNA 36 months 1. The subject is allergic to or has a contraindication to dexmedetomidine; 2. Subjects with renal and liver disease; 3. ASA physical status >3; 4. Severely depressed ventricular function or cardiac output; 5. The subject has cardiac conduction system disease (e.g. 2nd degree AV block); 6. The subject has received digoxin or beta-adrenergic antagonist on the day of the study; 7. The subject has Trisomy 21 (exaggerated risk of bradycardia); 8. The subject has severe coarctation of the aorta (risk of exaggerated vasoconstriction).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the early pharmacokinetics of nasal dexmedetomidine; | — |
Secondary
| Measure | Time frame |
|---|---|
| occurrence rate of bradycardia;occurrence rate of hypertension; | — |
Countries
China
Contacts
Public ContactBilian Li
Guangzhou Women and Chindren's Medical Center
Outcome results
None listed